Truist Financial Corp Intellia Therapeutics, Inc. Transaction History

Truist Financial Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 22, 2022	SELL	$58.27 - $118.99 $160,883 - $328,531	-2,761 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $15,416 - $21,169	-153 Reduced 5.25%	2,761 $326,000
Q3 2021 Nov 05, 2021	BUY	$132.37 - $176.78 $102,586 - $137,004	775 Added 36.23%	2,914 $391,000
Q2 2021 Aug 16, 2021	SELL	$60.88 - $161.91 $55,218 - $146,852	-907 Reduced 29.78%	2,139 $346,000
Q1 2021 May 17, 2021	SELL	$46.59 - $83.68 $153,607 - $275,892	-3,297 Reduced 51.98%	3,046 $244,000
Q4 2020 Feb 18, 2021	BUY	$18.83 - $63.53 $119,438 - $402,970	6,343 New	6,343 $346,000

313

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $997M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.